Last updated on August 2018

PGE1 as Additive Anticoagulant in ECMO-Therapy


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Extracorporeal Membrane Oxygenation | ADULT RESPIRATORY DISTRESS SYNDROME
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • minimum age 18 years
  • Veno-Venous- ECMO
  • Minimum of 24h planned ECMO- therapy

Exclusion Criteria:

  • Long- term therapy with other antiplatelet drugs including Acetyl Salicylic Acid
  • known Heparin induced thrombocytopenia
  • Bleeding diathesis = contraindication for heparin (e.g. GI-bleeding, Intracerebral bleeding)
  • Platelets < 50 G/L
  • Thromboplastin time < 50%
  • Pregnancy
  • Patient < 18 years
  • prothrombin time <50%

Drop out criteria:

  • Major bleeding (from Type 3 bleeding; see "primary objective")
  • Occurrence of HIT (4 T- Score: Number of platelets, development over time, manifestation of thrombosis, other reasons for thrombocytopenia [10])
  • Plt < 50 G/l

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.